Orthopedic Surgery, Department of Orthopaedics and Traumatology, Faculty of Medicine, Benha University, Benha, Qalyubia, Egypt.
Foot Ankle Int. 2020 Nov;41(11):1335-1341. doi: 10.1177/1071100720939066. Epub 2020 Aug 5.
The aim of this study was to evaluate the efficacy and safety of injection of allogeneic growth factors in patients with plantar fasciitis.
This study included 150 patients who were randomly divided into 2 equal groups; the patients were locally injected with allogeneic growth factors (GFs) (treatment group) or with saline 0.9% (control group). The patients were assessed using visual analog scale (VAS) and Foot Function Index-Revised short form (FFI-Rs) scores preinjection and 1, 3, 6, and 12 months postinjection. The patients were questioned about their satisfaction. Any adverse effects were recorded.
At baseline, there was no significant difference between both groups regarding the mean VAS and FFI-Rs scores. At 3-month follow-up, the reduction in mean VAS score was 87% in the treatment group and 55% in the control group ( < .001), and the reduction in mean FFI-Rs score was 62% in the treatment group and 40% in the control group ( < .001). Treatment group and study visit were significant factors affecting both VAS and FFI-Rs scores. Overall, 92% were satisfied in the treatment group, and 78.2% in the control group. Postinjection pain occurred in 5 patients in the treatment group.
This study provides Level I evidence regarding the efficacy and safety of allogeneic GF injection in patients with plantar fasciitis. However, additional studies are needed to evaluate their adverse effects, immunogenicity, and microbiological safety.
Level I, prospective randomized controlled case series.
本研究旨在评估同种异体生长因子注射治疗足底筋膜炎的疗效和安全性。
本研究纳入 150 例患者,随机分为两组,局部注射同种异体生长因子(GF)(治疗组)或 0.9%生理盐水(对照组)。患者在注射前及注射后 1、3、6 和 12 个月时采用视觉模拟评分(VAS)和足部功能指数修订短表(FFI-Rs)评分进行评估。询问患者满意度。记录任何不良反应。
基线时,两组 VAS 和 FFI-Rs 评分的均值无显著差异。在 3 个月随访时,治疗组 VAS 评分均值下降 87%,对照组下降 55%(<0.001),治疗组 FFI-Rs 评分均值下降 62%,对照组下降 40%(<0.001)。治疗组和研究访视点是影响 VAS 和 FFI-Rs 评分的显著因素。治疗组总体满意度为 92%,对照组为 78.2%。治疗组 5 例患者注射后出现疼痛。
本研究为同种异体 GF 注射治疗足底筋膜炎的疗效和安全性提供了 I 级证据。然而,需要进一步研究来评估其不良反应、免疫原性和微生物学安全性。
I 级,前瞻性随机对照病例系列研究。